IRMD
Iradimed Co
NASDAQ: IRMD · HEALTHCARE · MEDICAL DEVICES
$82.22
+0.43% today
Updated 2026-09-11
Market cap
$1.07B
P/E ratio
47.21
P/S ratio
12.38x
EPS (TTM)
$1.77
Dividend yield
0.91%
52W range
$67 – $107
Volume
0.1M
WallStSmart proprietary scores
48
out of 100
Grade: C
Sell
Investment rating
4.7
Growth
C7.3
Quality
B+9.5
Profitability
A+2.7
Valuation
F3/9
Piotroski F-Score
Weak
7.3
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$118.00
+43.52%
12-Month target
$65.52
-20.31%
Intrinsic (DCF)
$61.47
Margin of safety
-67.69%
0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 7.25 — safe zone
+ Profit margin 26.70% — above average
+ ROE 23.97% — strong efficiency
+ Free cash flow $5.75M — positive
Risks
- Piotroski 3/9 — weak financial health
- 67.69% above intrinsic value
- P/E 47.21x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $53.30M | $65.56M | $73.24M | $83.81M | $86.34M |
| Net income | $12.83M | $17.19M | $19.23M | $22.48M | $5.22M |
| EPS | — | — | — | — | $1.77 |
| Free cash flow | $8.17M | $5.46M | $17.62M | $17.18M | $5.75M |
| Profit margin | 24.06% | 26.22% | 26.26% | 26.82% | 26.70% |
Peer comparison
Smart narrative
Iradimed Co trades at $82.22. representing a P/E of 47.21x trailing earnings. Our Smart Value Score of 48/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 7.25, it sits in the safe zone. TTM revenue stands at $86.34M. with profit margins at 26.70%. Our DCF model estimates intrinsic value at $61.47.
Frequently asked questions
What is Iradimed Co's stock price?
Iradimed Co (IRMD) trades at $82.22, on a P/E of 47.2x and a P/S of 12.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Iradimed Co overvalued?
Iradimed Co carries a Smart Value Score of 48/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $61.47 against the $82.22 price, so on cash flow terms the market is paying a premium for Iradimed Co's growth. The Sell rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Iradimed Co (IRMD)?
The 12-month analyst consensus target is $118.00, about 43.5% above the current $82.22. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Iradimed Co (IRMD)?
Our DCF model estimates intrinsic value at $61.47, a -67.7% margin of safety versus today's $82.22. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Iradimed Co's revenue?
Iradimed Co's trailing twelve-month revenue is $86.34M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Iradimed Co's Altman Z-Score is 7.25, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio12.38x
ROE23.97%
Beta0.90
50D MA$91.66
200D MA$94.46
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—